Redhill Biopharma Ltd   (RDHL)
Other Ticker:  
Price: $0.5652 $-0.05 -8.247%
Day's High: $0.6196 Week Perf: 6.92 %
Day's Low: $ 0.55 30 Day Perf: -2.55 %
Volume (M): 571 52 Wk High: $ 4.98
Volume (M$): $ 323 52 Wk Avg: $1.29
Open: $0.62 52 Wk Low: $0.13

 Market Capitalization (Millions $) 338
 Shares Outstanding (Millions) 597
 Employees 158
 Revenues (TTM) (Millions $) 62
 Net Income (TTM) (Millions $) 72
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 0

Redhill Biopharma Ltd
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for the treatment of gastrointestinal diseases, cancer, and infectious diseases. Founded in 2009, the company is headquartered in Tel Aviv, Israel, and has offices in the United States and Europe.

RedHill's portfolio of drugs includes innovative and effective treatments for several conditions. Its lead product, Talicia, is a combination tablet designed to treat Helicobacter pylori (H. pylori) infection, a common cause of peptic ulcers. The company also markets EnteraGam, a medical food for the dietary management of chronic diarrhea and other gastrointestinal disorders. Other pipeline products include RHB-107, a treatment for multiple myeloma, and RHB-204, a potential therapy for pulmonary nontuberculous mycobacteria (NTM) disease.

RedHill has a unique drug development approach that involves repurposing existing drugs for new indications. This approach allows the company to leverage existing safety and efficacy data and expedite the regulatory approval process. RedHill also invests in innovative drug development programs that target unmet medical needs.

The company has a strong financial position, with a cash balance of $38.8 million at the end of 2020. In addition, RedHill has collaborated with several major pharmaceutical companies, including AstraZeneca, Pfizer, and Teva, to develop and commercialize its products.

RedHill is committed to advancing its mission of developing innovative drugs to improve patient outcomes. The company's dedication and focus on improving the lives of patients has led to numerous industry awards and recognitions, including the Frost & Sullivan 2020 North American New Product Innovation Award for Talicia.

   Company Address: 21 Ha?arba?a Street Tel Aviv 6473921
   Company Phone Number: 3-541-3131   Stock Exchange / Ticker: NASDAQ RDHL
   RDHL is expected to report next financial results on April 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stock Offering

RedHill Biopharma Raises $8 Million and Forges Ahead with Promising Pipeline

Published Fri, Jan 26 2024 5:46 PM UTC

In a recent announcement, RedHill Biopharma Ltd (NASDAQ: RDHL), a leading specialty biopharmaceutical company, confirmed the successful completion of its registered direct offering. The $8 million fundraise is expected to significantly bolster RedHill's financial resources, enhancing its ability to drive future growth and advance its innovative pipeline of therapeu...


Redhill Biopharma Ltd's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com